Efficacy Of HIF-PHI In The Treatment Of Renal Anemia In Maintenance Hemodialysis Patients In Xining Area

Objective: Hypoxia-inducible factor prolyl hydroxylase inhibitor(HIF-PHI),as a potential drug for the treatment of renal anemia,its discovery is a successful example of the transformation from basic medicine to clinical medicine,especially the listing of its 1.1 class new drug roxadustat,which has made more options for the treatment of renal anemia.At present,there are few related studies on roxadustat in areas with high altitudes,such as xining area.This study made a study on the effect of roxadustat in the treatment of renal anemia in patients with maintenance hemodialysis(MHD)in xining area.Discussion,so as to add new means and new methods for the treatment of renal anemia in the region,in order to bring relevant experience and reference for clinical treatment.Methods: A total of 60 patients who were treated with MHD in the Hemodialysis Center of Qinghai University Affiliated Hospital for more than 3months and complicated with renal anemia from November 2020 to November 2021 were selected as the research objects.The patients were divided into r Hu EPO group and HIF-PHI(roxadustat)group according to the random number table method.30 cases in each group.The r Hu EPO group was treated with subcutaneous injection of r Hu EPO,and the HIF-PHI(roxadustat)group was administered orally with roxadustat capsules.3 months in total.The content includes collecting before and after treatment general information of patients,laboratory tests including anemia,iron metabolism,Blood lipid,inflammatory factors and other indicators.Record the occurrence of adverse reactions.The statistical methods of t test and repeated measures analysis of variance were used to compare the changes of each laboratory index before treatment and 1 month,Changes of laboratory indicators at 2 and 3months after treatment.Results: There was no difference in the basic data indicators of anemia before treatment between the two groups of patients(P > 0.05).Compared with before treatment,the anemia indicators Hb,HCT and RBC in 2 groups were increased 3months after treatment(P < 0.05).TC,TG,HDL,LDL,CRP,WBC,NEUT%decreased in roxadustat group(P<0.05);TC,TG,HDL,LDL,CRP,WBC,NEUT%in r Hu EPO group had no significant difference(P>0.05).Fe,TIBC,UIBC,SF,and TSAT in roxadustat group increased(P>0.05);there was no significant difference in Fe,TIBC,UIBC,SF,and TSAT in r Hu EPO group(P>0.05).the rising trend of Hb,HCT and RBC in the roxadustat group was higher than that in the r Hu EPO group within the same treatment period(P<0.05).Due to the short follow-up period,none of the patients were lost to follow-up during the trial.Conclusions: 1.In the xining area,both HIF-PHI and r Hu EPO can improve renal anemia.During the same treatment period,HCT,RBC,Hb increased rapidly in HIF-PHI group.2.In this study,the incidence of adverse events of HIF-PHI is low and oral administration is convenient,so it is necessary to promote and exert its application value in clinical practice.